# Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

> **NCT03736447** · PHASE3 · COMPLETED · sponsor: **Aimmune Therapeutics, Inc.** · enrollment: 146 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** AR101 powder provided in capsules & sachets
- **BIOLOGICAL:** Placebo powder provided in capsules & sachets

## Key facts

- **NCT ID:** NCT03736447
- **Lead sponsor:** Aimmune Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-27
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736447, "Peanut Oral Immunotherapy Study of Early Intervention for Desensitization". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03736447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*